Bacil Pharma Limited Announces Resignation of Company Secretary and Compliance Officer

1 min read Updated on 01 Dec 2025, 06:37 PM

Reviewed by

Ashish TScanX News Team

Overview

Bhavana Phoolchand Tak, Company Secretary and Compliance Officer of Bacil Pharma Limited, has resigned effective December 1, 2025, to pursue other career opportunities. The company is seeking a replacement and will inform stock exchanges upon appointment. This change comes as Bacil Pharma reports substantial financial growth, with total assets increasing by 1869.23% and investments by 3466.67% year-over-year as of March 2025.

*this image is generated using AI for illustrative purposes only.

Bacil Pharma Limited has announced a significant change in its key managerial personnel. Bhavana Phoolchand Tak, who served as the Company Secretary and Compliance Officer, has tendered her resignation effective December 1, 2025. The company disclosed this information in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Resignation Details

Name of Key Managerial Personnel: Bhavana Phoolchand Tak
Position: Company Secretary and Compliance Officer
Effective Date of Resignation: December 1, 2025
Reason for Resignation: To pursue an alternate career opportunity outside the organization

The company has accepted Ms. Tak's resignation and confirmed that there are no other material reasons for her departure beyond the stated career move.

Company's Response

Bacil Pharma Limited has initiated the process of identifying a suitable candidate to fill the vacant position. The company has assured stakeholders that it will inform the stock exchanges once a replacement is appointed.

Financial Context

While this change in personnel is significant for corporate governance, it's worth noting Bacil Pharma's recent financial position. As of March 2025, the company's balance sheet shows:

Financial Metric	Value (in crore Rs)	YoY Change
Total Assets	25.60	1869.23%
Shareholder's Capital	25.40	2016.67%
Current Assets	2.90	2800.00%
Investments	21.40	3466.67%

The substantial year-over-year increases across these key financial metrics suggest that Bacil Pharma Limited has experienced significant growth or restructuring in the past year. This context underscores the importance of maintaining strong corporate governance and compliance practices during periods of rapid change.

As the company transitions to new leadership in its secretarial and compliance functions, investors and stakeholders will likely be keen to see how this change might impact the company's governance structure and regulatory compliance efforts going forward.

Bacil Pharma Limited is expected to provide further updates on the appointment of a new Company Secretary and Compliance Officer in due course.

Historical Stock Returns for Bacil Pharma